Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 study suggesting a potential role for GLP-1 agonists in PD.

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients. The finding contrasts with positive results from previous phase II ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease progression over 96 weeks of treatment, according to a phase 3 study ...

A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for the fast-growing drug ...

They were designed to treat diabetes, then prescribed for weight loss, and now—as researchers are finding—they might hold the ...

The findings of two recent studies give hope that the disease could one day be reversed in humans—but experts warn that this ...

GLP-1s are being studied for cardiovascular disease, liver conditions, kidney disease, and Alzheimer’s. Older approved GLP-1s from Novo Nordisk, Sanofi, and Amylin have been or are being ...

GLP-1 agonists like Wegovy, Ozempic, and Mounjaro might benefit heart and brain health—but research suggests they might also ...

GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

Popular diabetes medications, including GLP-1 drugs, may protect against Alzheimer's disease. ScienceDaily . Retrieved June 11, 2025 from www.sciencedaily.com / releases / 2025 / 04 / 250416135158.htm ...

Popular diabetes medications, including GLP-1 drugs, ... there is promising potential for GLP-1RAs and SGLT2is to be considered for Alzheimer’s disease prevention in the future.